Clinical trials · Riverside–San Bernardino, CA
Relapsed or Refractory Multiple Myeloma clinical trials in Riverside–San Bernardino
We’re tracking 131 recruiting relapsed or refractory multiple myeloma studies with a site in or near Riverside–San Bernardino — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT06675123RecruitingPhase 1
Pacritinib with a BTK inhibitor for mantle cell lymphoma
This trial tests a new combination of two targeted drugs (pacritinib plus a BTK inhibitor like ibrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. It may help if your current BTK inhibitor is no longer working well.
Duarte, CaliforniaAges 18 years+ - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
Duarte, CaliforniaAges 18 years+ - NCT07133997RecruitingPhase 1
Combination therapy for relapsed CD19+ B-cell leukemia
This trial tests a new combination of three drugs for patients with relapsed or treatment-resistant CD19-positive B-cell acute lymphoblastic leukemia. It aims to see if adding the drugs venetoclax and asparaginase to blinatumomab can improve outcomes.
Duarte, CaliforniaAges 12–55 - NCT06297941RecruitingPhase 1
Study of REM-422 for AML or high-risk MDS
This trial tests an experimental oral medication called REM-422 for people with AML (a type of blood cancer) that has not responded to treatment or has come back, or for those with high-risk MDS. The goal is to see if it is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06501196RecruitingPhase 1
Study of BH-30236 for leukemia and high-risk MDS
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT05263284RecruitingPhase 1
Study of 8-chloroadenosine plus venetoclax for relapsed or refractory AML
This trial tests a combination of two drugs, 8-chloroadenosine and venetoclax, for people with acute myeloid leukemia (AML) that has come back or not responded to prior treatments. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT07121946RecruitingPhase 1
Safety study of LTZ-301 for non-Hodgkin lymphoma
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
Duarte, CaliforniaAges 18 years+ - NCT05319314RecruitingPhase 1/Phase 2
Study drug for advanced colon cancer that has come back or failed
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
Duarte, CaliforniaAges 18 years+ - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Duarte, CaliforniaAges 18 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT04243785RecruitingPhase 1
Testing BTX-A51 for hard-to-treat AML or high-risk MDS
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
Duarte, CaliforniaAges 18 years+ - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Duarte, CaliforniaAges 18 years+ - NCT04634552RecruitingPhase 2
Talquetamab study for relapsed or refractory multiple myeloma
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
Duarte, CaliforniaAges 18 years+ - NCT04871607RecruitingPhase 2
Yttrium antibody plus chemotherapy for hard-to-treat Hodgkin lymphoma
This trial studies a targeted antibody therapy with yttrium, combined with intensive chemotherapy, for adults whose Hodgkin lymphoma did not respond well or came back. It may help by delivering cancer-killing radiation directly to lymphoma cells and preparing the body for treatment after transplant conditioning.
Duarte, CaliforniaAges 18 years+ - NCT05101551RecruitingPhase 1
Talazoparib with chemotherapy for relapsed childhood AML
This Phase 1 study tests whether talazoparib combined with chemotherapy is safe and potentially effective for children and young adults whose leukemia has come back or did not respond. It focuses on finding the best way to give the treatment and watching for side effects.
Duarte, CaliforniaAges Up to 21 years - NCT05370430RecruitingPhase 1
CAR T therapy targeting BAFF-R for certain NHL
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT05272384RecruitingPhase 1
Testing nivolumab plus ASTX727 for hard-to-treat lymphoma
This Phase 1 study tests whether adding ASTX727 to nivolumab can shrink relapsed or refractory B-cell lymphomas that have come back or did not respond to treatment. It also aims to find a safe dosing plan and see early signs of benefit in certain lymphoma types.
Duarte, CaliforniaAges 18 years+ - NCT05672147RecruitingPhase 1
CD33 CAR T cells for hard-to-treat AML
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
Duarte, CaliforniaAges 18 years+ - NCT05672251RecruitingPhase 2
Testing two antibody drugs for lymphoma that came back
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
Duarte, CaliforniaAges 18 years+ - NCT06054776RecruitingPhase 2
Acalabrutinib, obinutuzumab, and glofitamab for mantle cell lymphoma
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
Duarte, CaliforniaAges 18 years+ - NCT06121843RecruitingPhase 1
Study of CAR-T cell therapy in combinations for multiple myeloma
This trial tests a new CAR-T cell therapy (called arlocabtagene autoleucel) combined with other drugs for multiple myeloma that has returned or stopped responding. It aims to find a safe and effective dose while tracking how well the treatment works.
Duarte, CaliforniaAges 18 years+ - NCT06343792RecruitingPhase 2
Testing RLS-0071 for steroid-resistant acute graft-versus-host disease
This trial tests a new drug, RLS-0071, for people who are hospitalized with acute graft-versus-host disease that hasn't improved with steroids. It aims to see if the drug is safe and can help control the condition.
Duarte, CaliforniaAges 12 years+ - NCT06735664RecruitingPhase 1
Zanubrutinib and odronextamab for Richter's transformation
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Duarte, CaliforniaAges 18 years+
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Relapsed or Refractory Multiple Myeloma trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting relapsed or refractory multiple myeloma studies listed above.
- City of Hope Comprehensive Cancer Center · 22 studies
- University of California, Los Angeles (UCLA) · 2 studies
- Research Site
- Site 1091
- Site 1343
- UCLA / Jonsson Comprehensive Cancer Center
What taking part in a relapsed or refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting relapsed or refractory multiple myeloma studies in California.
Common questions
- Are there relapsed or refractory multiple myeloma clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 131 recruiting relapsed or refractory multiple myeloma studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a relapsed or refractory multiple myeloma study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New relapsed or refractory multiple myeloma studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.